These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 2905898)
1. Maintenance treatment with H2 receptor antagonists in patients with peptic ulcer disease: rarely justified in terms of cost or patient benefit. Howden CW BMJ; 1988 Nov; 297(6660):1393-4. PubMed ID: 2905898 [TBL] [Abstract][Full Text] [Related]
2. Maintenance treatment with H2 receptor antagonists in patients with peptic ulcer disease: reduces morbidity in a significant minority of patients. Wormsley KG BMJ; 1988 Nov; 297(6660):1392, 1394. PubMed ID: 2905897 [No Abstract] [Full Text] [Related]
3. Economic and health aspects of peptic ulcer disease and H2-receptor antagonists. Jensen DM Am J Med; 1986 Oct; 81(4B):42-8. PubMed ID: 2877574 [TBL] [Abstract][Full Text] [Related]
4. Medical treatment of peptic ulcers. Deveney CW; Deveney KE Surg Annu; 1985; 17():219-33. PubMed ID: 3883541 [TBL] [Abstract][Full Text] [Related]
5. Cimetidine and the cost of peptic ulcer in the Netherlands. Bulthuis R Eff Health Care; 1984 Apr; 1(6):297-311. PubMed ID: 10310799 [TBL] [Abstract][Full Text] [Related]
6. [Prevention of recurrence of peptic ulcers]. Fölsch UR Verh Dtsch Ges Inn Med; 1989; 95():319-22. PubMed ID: 2574921 [No Abstract] [Full Text] [Related]
10. [H1 and H2 histamine antagonists. Principles and rules of use]. Perault MC; Vandel B Rev Prat; 1996 Jun; 46(12):1547-50. PubMed ID: 8881170 [No Abstract] [Full Text] [Related]
11. Immediate eradication of Helicobacter pylori in patients with previously documented peptic ulcer disease: clinical and economic effects. Fendrick AM; McCort JT; Chernew ME; Hirth RA; Patel C; Bloom BS Am J Gastroenterol; 1997 Nov; 92(11):2017-24. PubMed ID: 9362183 [TBL] [Abstract][Full Text] [Related]
12. [The effects of an H2 receptor antagonist (cimetidine) in asthmatic patients]. Kobayashi H; Adachi M; Takahashi T Arerugi; 1985 Jan; 34(1):23-32. PubMed ID: 2859846 [No Abstract] [Full Text] [Related]
13. Short- and long-term management of peptic ulcer disease: current role of H2-antagonists. Brooks WS Hepatogastroenterology; 1992 Feb; 39 Suppl 1():47-52. PubMed ID: 1349553 [TBL] [Abstract][Full Text] [Related]
14. Drugs for treatment of peptic ulcers. Dajani EZ; Trotman BW J Assoc Acad Minor Phys; 1992; 3(3):78-88. PubMed ID: 1353999 [TBL] [Abstract][Full Text] [Related]
15. [Experimental study of Dolispan in the therapy of peptic ulcer]. Manolov P; Todorov S Eksp Med Morfol; 1974; 13(1):36-9. PubMed ID: 4151718 [No Abstract] [Full Text] [Related]
16. [Effectiveness and safety of long-term H2-receptor antagonist maintenance therapy]. Wormsley KG Orv Hetil; 1992 Nov; 133(47):3013-7. PubMed ID: 1359491 [TBL] [Abstract][Full Text] [Related]
17. [Currents aspects of H2 receptor antagonists in the treatment of ulcers]. Debongnie JC Acta Gastroenterol Belg; 1992; 55(5-6):415-22. PubMed ID: 1363166 [TBL] [Abstract][Full Text] [Related]
18. [Pharmacoeconomics in the therapy of peptic ulcer]. Tesar T; Foltán V; Huorka M Ceska Slov Farm; 2002 Mar; 51(2):78-83. PubMed ID: 11928281 [TBL] [Abstract][Full Text] [Related]
19. [Histamine as the principal pathogenetic factor in gastroduodenal ulcer. Research priorities]. Businco L Minerva Med; 1980 Sep; 71(31):2193-7. PubMed ID: 6158718 [TBL] [Abstract][Full Text] [Related]
20. High IgE serum levels and "peptic" ulcers: clinical and functional approach. De Lazzari F; Mancin O; Plebani M; Venturi C; Battaglia G; Vianello F; Galliani EA; Di Mario F; Naccarato R Ital J Gastroenterol; 1994; 26(1):7-11. PubMed ID: 7912969 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]